RESUMO
Objective: To observe the clinical effects of kanglaite capsules combined with transcatheter arterial chemoembolization (TACE) on patients with advanced unresectable hepatocellular carcinoma (HCC). Methods: Sixty-five cases were divided into 2 groups at random. In treatment group, 32 patients received kanglaite capsules after TACE and 33 patients in control group were treated with TACE singly. The objective response rate (RR), serum alpha fetoprotein (AFP), peripheral blood T lymphocyte subsets (T-1s), quality of life (QOL), time to progression (TIP), and adverse reaction were observed. Results: The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups (P>0.05). Treatment group was superior to control group in the quality of life (QOL), the time to progression (TIP), peripheral blood T lymphocyte subsets (CD3+, CD4+, CD4+/CD8+ ratio), and frequency of adverse reactions in liver. The difference was significant (P<0.05). Conclusion: Kanglaite capsules combined with TACE was an effective method for primary HCC patients who have lost the surgical chance.